Partners and Collaborators

At Simulations Plus, we strive to improve the productivity of science-based research and development through the use of our technology. We realize, however, that this is something we cannot do alone, and we actively collaborate with a variety of universities, contract research organizations (CROs), distributors, and government agencies to help meet our (and their) client’s goals. Below is a partial list of the partnerships we have formed to continue advancing the use of modeling & simulation approaches.

Interested in working with us and/or utilizing our technology to support clients? Our team is ready to discuss your needs today.

Academic Collaborators
We are always interested in speaking with professors & students on ways in which we can support academic research and coursework:

The University of Buffalo, UB Center of Excellence in Pharmacokinetics and Pharmacodynamics

University of Maryland

University of Florida,
College of Pharmacy

CRO Partners
The demand for QSAR/PBPK modeling support continues to grow, and we encourage CROs to explore incorporating our software to assist with their client projects:

Admescope: Oulu, Finland

Aptuit: Verona, Italy

Bend Research: Bend, OR, USA

Covance: Madison, WI, USA

Cyprotex: Macclesfield, United Kingdom

PAREXEL: Uxbridge, United Kingdom

PharmaDirections: Cary, NC, USA

PhinC Development: Massy, France

Quotient Clinical: Nottingham, United Kingdom

RILD: Shanghai, China

Solvo Biotechnology: Budapest, Hungary

Sygnature Discovery: Nottingham, United Kingdom

WuXi Apptec: Shanghai, China

We have strong distributor channels in Japan and China that provide local technical & marketing support for us, and we are always on the lookout to establish similar relationships in other territories:


Electrolab India Pvt. Ltd.: Mumbai, India

Northern Science Consulting: Hokkaido, Japan

PharmoGo Co. Ltd.: Shanghai, China

Quantum Bio Solutions: South Korea

Government Collaborations
Much of the momentum behind the increased use of PBPK modeling has been driven by regulatory agencies around the world, who all have access to our software, and we are happy to partner with several of them on different projects:

National Toxicology Program: We have been collaborating with scientists from the U.S. EPA/NIEHS/NTP for several years on the use of GastroPlus® and ADMET Predictor® to efficiently screen the Tox21 library – more details can be found here:

U.S. FDA: We have been very fortunate to receive 2 funded grant awards from the FDA to continue to enhance the GastroPlus platform, and most divisions have access to the software – more details can be found here:

National Institutes of Health: We are thankful the NIH supports our mission to help modernize drug development and reduce the time and costs associated with developing new therapies. Building on our expertise in drug-induced liver injury and nonalcoholic fatty liver disease, RENAsym® will expand our Quantitative Systems Pharmacology (QSP) offerings to include potential damage to the kidney. More details can be found here: